Febrile convulsion risk increased post-MMR vaccine
- PDF / 142,118 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 77 Downloads / 171 Views
1
Febrile convulsion risk increased post-MMR vaccine Between 6 and 11 days following administration of the measles, mumps rubella (MMR) vaccine there is an increased risk of febrile convulsions among children, according to researchers from the UK. Incidence of post-immunisation severe neurological disease Age/vaccine
2–11 months Hib-DTP
MenC
12–35 months MMR
MenC
Risk period (days)
No. of cases
Relative incidence (95% CI)
0–3
0
0–7
2
0–3
0
0–3
0
0.00 (0.00–1.92) 0.97 (0.22–4.30) 0.00 (0.00–25.5) 0.00 (0.00–1.70)
6–11
6
15–35
5
0–3
0
0–7
1
5.68 (2.31–13.97) 1.34 (0.52–3.47) 0.00 (0.00–7.92) 1.28 (0.17–9.75)
The researchers used data from a 3-year prospective study of children aged 2–35 months with febrile convulsions and/or encephalitis; data were linked to each child’s vaccination history. The risk periods evaluated in this study were: 0–3 and 0–7 days after receiving Hib-DTP* vaccine or meningococcal vaccine group C conjugate (MenC), and 6–11 and 15–35 days after MMR vaccination. A total of 157 cases that met the case definition were evaluated, from 155 children. At 6–11 days post-MMR vaccine, there was an increased risk of severe neurological disease among children aged 12–35 months [see table]. The 6 cases of severe neurological disease all met the criteria for febrile convulsions. * Haemophilus influenza type b - diphtheria, tetanus, whole cell pertussis Ward KN, et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics 120: 314-321, No. 2, Aug 801093059 2007
0114-9954/10/1176-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 3 Nov 2007 No. 1176
Data Loading...
